Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

被引：3

作者：

Mai, Elias K. ^{[1
]}

Hielscher, Thomas ^{[2
]}

Bertsch, Uta ^{[1
]}

Schlenzka, Jana ^{[1
]}

Salwender, Hans J. ^{[3
]}

Munder, Markus ^{[4
]}

Gerecke, Christian ^{[5
]}

Duehrsen, Ulrich ^{[6
]}

Brossart, Peter ^{[7
]}

Neben, Kai ^{[8
]}

Hillengass, Jens ^{[1
]}

Raab, Marc S. ^{[1
]}

Merz, Maximilian ^{[1
]}

Baertsch, Marc-Andrea ^{[1
]}

Jauch, Anna ^{[9
]}

Hose, Dirk ^{[1
]}

Martin, Hans ^{[10
]}

Lindemann, Hans-Walter ^{[11
]}

Blau, Igor W. ^{[12
]}

Scheid, Christof ^{[13
]}

Weisel, Katja C. ^{[14
]}

Goldschmidt, Hartmut ^{[1
,15
]}

机构：

[1] Univ Clin Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[2] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[3] Asklepios Hosp Hamburg Altona, Dept Hematol & Oncol, Hamburg, Germany

[4] Univ Med Ctr Mainz, Dept Internal Med 3, Mainz, Germany

[5] Helios Hosp Berlin Buch, Dept Hematol & Oncol, Berlin, Germany

[6] Univ Clin Essen, Dept Hematol, Essen, Germany

[7] Univ Hosp Bonn, Bonn, Germany

[8] Klinikum Baden Baden, Dept Hematol & Oncol, Baden Baden, Germany

[9] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[10] Goethe Univ Frankfurt, Dept Med Hematol Oncol, Frankfurt, Germany

[11] Katholisches Krankenhaus Hagen, Dept Hematol & Oncol, Hagen, Germany

[12] Charite Univ Med Berlin, Med Clin, Berlin, Germany

[13] Univ Hosp Koln, Dept Internal Med 1, Cologne, Germany

[14] Univ Hosp Tubingen, Dept Hematol Oncol & Immunol, Tubingen, Germany

[15] Natl Ctr Tumorerkrankungen NCT Heidelberg, Heidelberg, Germany

来源：

LEUKEMIA | 2019年 / 33卷 / 01期

关键词：

D O I：

10.1038/s41375-018-0195-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：258 / 261

页数：4

共 50 条

[41] Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Shah, Jatin J.
Feng, Lei
Manasanch, Elisabet E.
Weber, Donna M.
Thomas, Sheeba K.
Turturro, Francesco
Alexanian, Raymond
Shah, Nina
Popat, Uday R.
Nieto, Yago
Bashir, Qaiser
Qazilbash, Muzaffar H.
Champlin, Richard E.
Orlowski, Robert Z.
BLOOD, 2014, 124 (21)
[42] Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Shah, Jatin J.
Feng, Lei
Manasanch, Elisabet E.
Weber, Donna
Thomas, Sheeba K.
Turturro, Francesco
Shah, Nina
Popat, Uday R.
Nieto, Yago
Bashir, Qaiser
Munoz, Silvia C.
Landry, Ashley
Mendoza, Kathleen
Champlin, Richard E.
Qazilbash, Muzaffar H.
Orlowski, Robert Z.
BLOOD, 2015, 126 (23)
[43] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
Mehra, Maneesha
Cote, Sarah
Kampfenkel, Tobias
Nair, Sandhya
BLOOD, 2019, 134
[44] Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma
Hungria, Vania T. M.
Moura, Fernanda Lemos
Soares, Paulo
Lima, Juliana Souza
Ricci, Lisa Aquaroni
Nucci, Fabio Moore
Oliveira Ribeiro, Eduardo Flavio
Crusoe, Edvan de Queiroz
Lima, Marinus de Moraes
Pessoa de Magalhaes Filho, Roberto Jose
Arrais-Rodrigues, Celso
Bhaumik, Amitabha
Parekh, Trilok
Borgsten, Fredrik
Carson, Robin
Trufelli, Damila C.
Costa, Abel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S230 - S230
[45] The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
Zamagni, Elena
Tacchetti, Paola
Deias, Paola
Patriarca, Francesca
PHARMACEUTICALS, 2020, 13 (12) : 1 - 12
[46] A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson Jr, Larry D.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
FUTURE ONCOLOGY, 2022, 18 (40) : 4443 - 4456
[47] Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma
Perrot, Aurore
PRESSE MEDICALE, 2025, 54 (01):
[48] Induction Treatment in Transplant-eligible Multiple Myeloma
Quinn, J.
Glavey, S.
Comerford, C.
Murphy, P.
HEMASPHERE, 2021, 5 (05):
[49] Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study
Sonneveld, Pieter
Dimopoulos, Meletios
Boccadoro, Mario
Hang Quach
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels
Liu, Yanfang
Wang, Jianping
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Rodriguez-Otero, Paula
Blade, Joan
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S246 - S246
[50] Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
Joseph, Nisha
Almaula, Dhwani
Gleason, Charise
Heffner, Leonard
Boise, Lawrence H.
Kaufman, Jonathan L.
Lonial, Sagar
Nooka, Ajay
BLOOD, 2017, 130

← 1 2 3 4 5 →